濮阳东方男科公交路线(濮阳东方医院男科割包皮价格标准) (今日更新中)

SAN DIEGO (KGTV) - A student at Nazareth School San Diego in Mission Valley is in the hospital with meningococcal disease, county health officials said Friday. The County Health and Human Services Agency (HHSA) said it is reaching out to anyone who came in close contact with the child at the K-8 school. Antibiotics are not being recommended for those who are not at risk. “While meningococcal disease can be serious and deadly, it is not spread through casual contact. Therefore, the risk to those who were not in close, direct contact is minimal,” said Wilma Wooten, M.D., M.P.H., County public health officer. “We want to make sure students are up to date on immunizations and are asking people in the school community to look for the signs and symptoms of the disease.” Meningococcal disease is caused by a bacteria and spread through close contact including sharing drinking glasses, eating utensils, and smoking or vaping equipment. The bacteria can cause serious and potentially life-threatening illness. Symptoms include fever, headache, sensitivity to light and noise, a stiff neck, and a rash. Anyone who develops the symptoms should get medical help, health officials said. 1193

SAN DIEGO (KGTV) - A team led by Scripps Research has yielded positive results in a new research study involving antibodies.Researchers say they've worked to isolate the most potent antibodies in the blood of recovered COVID-19 patients. The study was published in "Science."Dennis Burton, the study's co-author, says once they identified the most potent antibodies, they cloned them."You clone the really good ones, and then you make lots and lots of them in production facilities and then use as a standard to protect and-or treat Covid-19," Burton said.They've tested the cloned antibodies, or monoclonal antibodies, on animals, and they've yielded positive results. They hope to conduct human testing early next year.When asked if it is similar to antibody treatments from convalescent plasma donations, Burton says what they're making is more efficient and can be produced for masses.He says the monoclonal antibodies could be used as a preventive measure given to uninfected but at-risk people before a vaccine is available, and could even be useful for people that may not respond well to a vaccine.He also says the monoclonal antibodies could be used to design better vaccines by giving researchers a better idea of which antibodies are most effective. 1268

SAN DIEGO (KGTV) -- An Escondido man who pleaded guilty to firing several rounds into the air in a crowded area when he couldn't get tickets to an Ice Cube concert was sentenced to three years behind bars Wednesday. Daniel Elizarraras, 22, pleaded guilty to discharging a gun at the Del Mar Fairgrounds in early September of 2018. Authorities say Elizarraras raised the gun before shooting into the air while he was in a large crowd near the ticket booth. Elizarraras was shot three times in the torso and once in the arm after he pointed the gun at a deputy. RELATED: Man admits he opened fire before Ice Cube concert at Del Mar FairgroundsElizarraras was facing up to 19 years behind bars, but a charge of assault on a peace officer with a semi-automatic weapon was dismissed as part of his plea. Defense Attorney Pedro Bernal said Elizarraras was severely depressed and trying to kill himself by suicide by cop. They asked for a lower sentence.However, the prosecution said he acted violently, causing chaos, and the situation could have been much worse.Judge Kathleen Lewis agreed saying, "I think it’s amazing that no one was injured or killed in this circumstance.”Before the shooting, officials said the venue was at capacity and began turning people away from the horse races and concert. Fights erupted between security guards and would-be concert-goers who were upset that they wouldn’t be allowed into the show. RELATED: Rapper Ice Cube responds to pre-concert shooting at Del Mar Fairgrounds in San Diego CountyDeputy Tyler Eikermann saw Elizarraras raise a silver-colored firearm and shoot into the air in a large crowd by a ticket booth. That’s when the deputy pulled out his Taser, which was ineffective. Authorities say Eikermann pulled out his gun and shot Elizarraras four times. City News Service contributed to this report. 1851

SAN DIEGO (KGTV) - After moving to San Diego almost three years ago, Derek and Terri Ruff are on a mission to experience everything the city has to offer. “Yes we are, it’s fantastic! We hardly leave the county, there’s just so much to do," said Derek.The couple moved here from New Mexico, and for nine years Derek's colon cancer seemed to be behind them. “I won’t say cancer-free, but I didn’t have any symptoms for years, until last May, whenever I came in for a checkup, and they discovered cancer again," said Derek.It was stage IV metastatic colon cancer.“It’s a lot. It’s a tough diagnosis, it’s really difficult to live through.”After three months of aggressive chemotherapy, Ruff's condition only got worse. His journey brought him to UC San Diego Health's Moores Cancer for a clinical trial, which unfortunately did not work. But he Ruff became a candidate for another trial involving natural killer cells created from stem cells.“These are patients who don’t have a lot of good options in terms of chemotherapy or immunotherapy," said Dr. Sandip Patel, a medical oncologist who is leading the trial at UCSD. Decades of research on natural killer cells have culminated in the new cancer treatment being developed by San Diego-based Fate Therapeutics.Fate is the first to mass produce cancer-killing cells from a type of stem cell called a human-induced pluripotent stem cell (iPSC). "The concept of utilizing the stem cells that are within us, within our blood factory, within our blood marrow, to create a master bank of cells that we can utilize to program in different ways to fight cancer with cellular immunotherapy."The off-the-shelf, iPSC-derived natural killer cell cancer immunotherapy received U.S. Food and Drug Administration approval to move into clinical trials in November 2018. Ruff is the first person in the world to receive the treatment and got his first dose in February.“Being the first is exciting but it was less so hearing that you have stage iv cancer and you don’t have much of a future, and now I feel hopeful, again," said Ruff.While it's too early to tell if the treatment is working, researchers are hopeful this treatment will one day help many cancer patients. 2212

SAN DIEGO (KGTV) - An early morning collision involving a tractor-trailer stopped traffic near Mission Valley Saturday.The big rig crash on northbound Interstate 15 near the I-8 connector blocked all lanes, creating a complete standstill of the morning commute.Traffic was being diverted onto I-8, however, all lanes reopened just before 6 a.m. It's not clear how the collision occurred.TRAFFIC MAP: FIND A NEW ROUTEIt's not clear if anyone was seriously injured in the crash.10News is monitoring this breaking news story. 530

来源：资阳报